Under the agreement, the two companies will evaluate the efficacy of combining GI Innovation's immunotherapy agent GI-102 with MSD's immunotherapy drug Keytruda in clinical trials involving patients with resistant liver cancer, melanoma, and kidney cancer.
GI-102 is described by GI Innovation as a therapeutic agent with the ability to increase the number of immune cells by an average of five times, demonstrating potent immune cell proliferation capabilities.
reporter
Kim Joo-heon
jhkim123@ajunews.com
